The meeting objectives are designed to introduce the audience to the latest information on targeted therapies, immunotherapies, and emerging treatments in early development. The major emphasis will be on clinical aspects of cancer treatment in the 21st century with discussion of significant scientific advances underlying the novel approaches still in preclinical development.
Os 30 primeiros associados da SBOC que tiverem interesse irão ganhar inscrição para o Congresso! Envie email para [email protected] com nome completo, especialidade, local de trabalho e número de passaporte.